Proneuron is the first company to harness the power of the body's own immune system for the treatment of neurological disorders, which until now were considered incurable.
Company
Proneuron Biotechnologies is enrolling patients suffering from complete spinal cord injuries to participate in a Phase II multi-center clinical study. Patients within 14 days of injury will be implanted with ProCord. Proneuron Biotechnologies, a Delaware company, is in advanced stages of clinical development in a number of attractive neurological markets. Proneuron is the first company to harness the power of the body's own immune system for the treatment of debilitating central nervous system (CNS) disorders. The concept of helping the body to "cure" itself, offers hope to the millions of victims of nervous system-related disorders. Proneuron Biotechnologies is developing therapies for neurological disorders, including spinal cord injury (SCI), other central nervous system trauma and back injuries. Our products are based on proprietary technology for modulating the interaction between the nervous system and the immune system. Proneuron is enrolling a total of 61 patients suffering from complete spinal cord injuries in a Phase II multi-center clinical study. Patients will be implanted with ProCord. Study sites must be informed of a candidate patient within a few days of the spinal cord injury to allow time to complete the necessary tests and procedures within 14 days of injury.
Home Page
   Company
 
      Technology
 
       Therapies
 
       Clinical Studies
 
      News & Events
 
     Links
 
   Careers
 
Mission & Strategy | Collaborations | Company's Milestones | Contact Us |

Introduction

Proneuron Biotechnologies, a Delaware company, is in advanced stages of clinical development in a number of attractive neurological markets. Proneuron is the first company to harness the power of the body's own immune system for the treatment of debilitating central nervous system (CNS) disorders. The Company was founded in 1996 based upon the groundbreaking research of Professor Michal Schwartz of the Weizmann Institute of Science, who demonstrated the role of immune response in normal and pathological conditions in the CNS. Proneuron is determined to establish itself as a fully integrated company that will independently develop and commercialize therapies for niche CNS disorders.

Proneuron is currently focusing its expertise in cell therapy and neuroimmunology on the development and commercialization of treatments for spinal cord injuries (SCI) as well as other neurological disorders, which until now were considered incurable.

Proneuron's double layer business approach - a fully integrated niche CNS company and a source for product licensing for large pharma and biotech players, creates a wealth of potential revenue sources with a balanced risk profile.



Disclaimer | Site Map | Home Page| Contact Us Top of page
 

Proneuron Biotechnologies is engaged in research
related to spinal cord injuries and paralysis cure
.






























Our friends on the web
Judaica Shop
Spinal Cord Injury
Virtual Keyboard
Spinal Cord Injuries
Flowers Israel
Mobile NoteTaker
Marine Construction
Australia Flowers
Rugged Computers
Mobile Phone Disabler
Digital Pen